The ASCO Post captured initial reactions to the Oncologic Drugs Advisory Committee (ODAC) recommendation that the breast cancer indication for bevacizumab (Avastin) be revoked in interviews with ODAC voting members, breast cancer specialists, oncologists in private practice, third-party payers, and a patient advocate. These reactions are available here at ASCOPost.com and in the September print issue of The ASCO Post.

(Photos, L to R: Sandra M. Swain, MD; Harold J. Burstein, MD; Wyndham Wilson, MD, PhD; Edith P. Perez, MD; Matthew Ellis, MD, BChir, PhD; Kathy S. Albain, MD, FACP; Musa Mayer; Steven Vogl, MD; Joanne Mortimer, MD; Cary Presant, MD, FACP; Eric P. Winer, MD)

Read More

The Oncologic Drugs Advisory Committee (ODAC) of the FDA has recommended that the Agency revoke approval of bevacizumab (Avastin) in first-line treatment of metastatic breast cancer. The FDA will decide whether or not to accept this recomendat...

Read More